Tumors
8 competing products in clinical development for Tumors.
Pipeline by Phase
Phase 16
Phase 1/22
All Products (8)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Lenvatinib + Pembrolizumab | Eisai | Phase 1/2 | Completed | 32 |
| Lenvatinib + Lenvatinib + Lenvatinib + Lenvatinib + Lenvatinib + Ifosfamide + Etoposide + Ifosfamide + Etoposide | Eisai | Phase 1/2 | Completed | 32 |
| Cixutumumab | Eli Lilly | Phase 1 | Completed | 29 |
| AGS-22M6E + ASG-22CE | Astellas Pharma | Phase 1 | Completed | 29 |
| Lenvatinib + Midazolam | Eisai | Phase 1 | Completed | 29 |
| E7090 | Eisai | Phase 1 | Completed | 29 |
| E7046 | Eisai | Phase 1 | Terminated | 21 |
| ZN-c3 + Bevacizumab + Pembrolizumab | Zentalis Pharmaceuticals | Phase 1 | Withdrawn | 11 |